miR-451a-loaded extracellular vesicles

miR-451a-loaded extracellular vesicles (EVs), including exosomes and synthetic liposomes, are being investigated as a novel therapeutic platform to attenuate heme-induced inflammation and cellular stress. Developed by researchers at the Morehouse School of Medicine and the University of Louisville, this approach delivers miR-451a mimic oligonucleotides to vascular endothelial cells and macrophages. miR-451a acts by post-transcriptionally downregulating key inflammatory mediators, including the interleukin-6 receptor (IL-6R), Toll-like receptor 4 (TLR4), and macrophage migration inhibitory factor (MIF). By mitigating the pro-inflammatory cascade triggered by excess free heme, these engineered vesicles hold therapeutic potential for reducing morbidity and mortality associated with severe malaria and sickle cell disease (SCD).

Other names

miR-451a-loaded exosomesmiR451a-loaded exosomesmiR 451a-loaded exosomesmiR-451a-loaded liposomesmiR451a-loaded liposomesmiR 451a-loaded liposomesmiR-451a-loaded sEVsmiR451a-loaded sEVsmiR 451a-loaded sEVsmiR-451a-loaded small extracellular vesiclesmiR451a-loaded small extracellular vesiclesmiR 451a-loaded small extracellular vesicles